BMY · Categories · Dividends
BMY - Dividend announcements
Bristol-Myers Squibb Company (BMY) dividend announcements - real-time wire coverage filtered to Dividends only.
Recent Dividends for BMY
- Bristol Myers Squibb Announces DividendBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on May 1, 2026, to stockholders of record at the close of business on April 2, 2026. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information about Bristol Myers Squibb, visit u
- Bristol Myers Squibb Announces Dividend IncreaseBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on February 2, 2026, to stockholders of record at the close of business on January 2, 2026. This quarterly dividend represents a 1.6% increase over last year's quarterly rate of sixty-two cents ($0.62) per share. At this quarterly dividend rate, subject to the normal quarterly review by the Board of Directors, the annual dividend rate for the fiscal year 2026 is $2.52 per share. This marks the 17th consecutive year that the company has increased its dividend and the 94
- Bristol Myers Squibb Announces DividendBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on November 3, 2025, to stockholders of record at the close of business on October 3, 2025. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on December 1, 2025, to stockholders of record at the close of business on November 4, 2025. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discov
- Bristol Myers Squibb Announces DividendBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on August 1, 2025, to stockholders of record at the close of business on July 3, 2025. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on September 2, 2025, to stockholders of record at the close of business on August 5, 2025. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, de
- Bristol Myers Squibb Announces DividendBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on May 1, 2025, to stockholders of record at the close of business on April 4, 2025. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on June 2, 2025, to stockholders of record at the close of business on May 6, 2025. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and d
- Bristol Myers Squibb Announces Dividend IncreaseBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on February 3, 2025, to stockholders of record at the close of business on January 3, 2025. This quarterly dividend represents a 3.3% increase over last year's quarterly rate of sixty cents ($0.60) per share. At this quarterly dividend rate, subject to the normal quarterly review by the Board of Directors, the annual dividend rate for the fiscal year 2025 is $2.48 per share. This marks the 16th consecutive year that the company has increased its dividend and the 93rd co
- Bristol Myers Squibb Announces DividendBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company. The dividend is payable on November 1, 2024, to stockholders of record at the close of business on October 4, 2024. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on December 2, 2024, to stockholders of record at the close of business on November 5, 2024. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, devel
- Bristol Myers Squibb Announces DividendBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company. The dividend is payable on August 1, 2024, to stockholders of record at the close of business on July 5, 2024. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on September 3, 2024, to stockholders of record at the close of business on August 6, 2024. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop,
- Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 BillionAcquisition centered on KarXT, which was invented at PureTech, as a potential first-in-class treatment for schizophrenia in adults PureTech to receive approximately $293 million gross proceeds from Karuna equity position in addition to being eligible for further milestones and royalty payments based on KarXT regulatory & commercial successes PureTech intends to provide an update in the coming days regarding its capital return plans PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, today announced the completed acquisition of its Founded Entity, Karuna Therapeutics, Inc. ("Karuna"), by Bristol Myers Squibb (NYSE:BMY)
- Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience PortfolioKarXT, Karuna's Lead Asset, Is a Potential First-in-Class Treatment for Schizophrenia with Multi-Billion Dollar Sales Potential Across Multiple Indications Bristol Myers Squibb (NYSE:BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. ("Karuna"). With the acquisition's completion, Karuna shares have ceased trading on the Nasdaq Global Select Market and Karuna is now a wholly owned subsidiary of Bristol Myers Squibb ("BMS"). "We are excited to expand our neuroscience portfolio as we welcome Karuna to Bristol Myers Squibb," said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. "Importantly, this transaction aligns with o
- Bristol Myers Squibb Announces DividendBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company. The dividend is payable on May 1, 2024, to stockholders of record at the close of business on April 5, 2024. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on June 3, 2024, to stockholders of record at the close of business on May 7, 2024. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver
- Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBioTransaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb's Leading Oncology Franchise Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types Gains Robust IND Engine and State of the Art Radiopharmaceutical Manufacturing Capabilities PRINCETON, N.J. and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Bristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced a definitive merger agreement under which
- Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBioTransaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs, to Bristol Myers Squibb's Leading Oncology Franchise Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types Gains Robust IND Engine and State-of-the-Art Radiopharmaceutical Manufacturing Capabilities Bristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per shar
- Bristol Myers Squibb Announces Dividend IncreaseBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company. The dividend is payable on February 1, 2024, to stockholders of record at the close of business on January 5, 2024. This quarterly dividend represents a 5.3% increase over last year's quarterly rate of fifty-seven cents ($0.57) per share. At this quarterly dividend rate, subject to the normal quarterly review by the Board of Directors, the annual dividend rate for the fiscal year 2024 is $2.40 per share. This marks the 15th consecutive year that the company has increased its dividend and the 92nd
- Bristol Myers Squibb Announces DividendBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents ($0.57) per share on the $0.10 par value common stock of the company. The dividend is payable on November 1, 2023, to stockholders of record at the close of business on October 6, 2023. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on December 1, 2023, to stockholders of record at the close of business on October 31, 2023. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discov
- Bristol Myers Squibb Announces DividendBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents ($0.57) per share on the $0.10 par value common stock of the company. The dividend is payable on August 1, 2023, to stockholders of record at the close of business on July 7, 2023. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on September 1, 2023, to stockholders of record at the close of business on August 1, 2023. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, de
- Bristol Myers Squibb Announces DividendBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents ($0.57) per share on the $.10 par value common stock of the company. The dividend is payable on May 1, 2023, to stockholders of record at the close of business on April 10, 2023. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on June 1, 2023, to stockholders of record at the close of business on May 2, 2023. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and de
- Bristol Myers Squibb Announces Dividend IncreaseBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents ($0.57) per share on the $.10 par value common stock of the company. The dividend is payable on February 1, 2023 to stockholders of record at the close of business on January 6, 2023. This quarterly dividend represents a 5.6% increase over last year's quarterly dividend rate of fifty-four cents ($0.54) per share. At this quarterly dividend rate, subject to the normal quarterly review by the Board of Directors, the annual dividend rate for the fiscal year 2023 is $2.28 per share. This marks the fourteenth consecutive fiscal year that the company has increased it
- Bristol Myers Squibb Announces DividendBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-four cents ($0.54) per share on the $.10 par value common stock of the company. The dividend is payable on November 1, 2022 to stockholders of record at the close of business on October 7, 2022. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable December 1, 2022, to stockholders of record at the close of business on November 8, 2022. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, devel
- Bristol Myers Squibb Announces DividendBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-four cents ($0.54) per share on the $.10 par value common stock of the company. The dividend is payable on August 1, 2022 to stockholders of record at the close of business on July 1, 2022. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable September 1, 2022, to stockholders of record at the close of business on August 9, 2022. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, an
- Bristol Myers Squibb Announces DividendBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-four cents ($0.54) per share on the $.10 par value common stock of the company. The dividend is payable on May 2, 2022 to stockholders of record at the close of business on April 1, 2022. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable June 1, 2022, to stockholders of record at the close of business on May 10, 2022. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deli
- Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase AuthorizationBristol Myers Squibb (NYSE:BMY) today announced that on December 10, 2021, its Board of Directors approved an increase in the quarterly dividend and authorized an additional multi-year share repurchase program. "The company's financial position is strong, and we remain committed to a consistent, balanced capital allocation strategy," said Giovanni Caforio, board chair and chief executive officer, Bristol Myers Squibb. "With significant free cash flow of $45 billion to $50 billion expected between 2021 and 2023, investment in business development continues to be a key priority for the company in driving innovation and sustained growth as we return capital to shareholders through the dividen
- Bristol Myers Squibb Announces DividendBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of forty-nine cents ($0.49) per share on the $.10 par value common stock of the company. The dividend is payable on November 1, 2021 to stockholders of record at the close of business on October 1, 2021. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable December 1, 2021 to stockholders of record at the close of business on November 9, 2021. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develo
- Bristol Myers Squibb Announces DividendBristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of forty-nine cents ($0.49) per share on the $.10 par value common stock of the company. The dividend is payable on August 2, 2021 to stockholders of record at the close of business on July 2, 2021. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable September 1, 2021 to stockholders of record at the close of business on August 10, 2021. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver
- Bristol Myers Squibb Reports First Quarter Financial Results for 2021Reports First Quarter Revenues of $11.1 Billion, an Increase of 3% YoY; Revenue Increase of 8% Excluding COVID-19 Related Buying Patterns from Prior Year Period Posts First Quarter Earnings Per Share of $0.89 and Non-GAAP EPS of $1.74 Strengthens Leadership in Immuno-Oncology with Multiple Regulatory and Data Milestones for Opdivo and Yervoy Delivers Positive Results from Phase 2/3 RELATIVITY-047 Trial Evaluating Relatlimab and Opdivo for Previously Untreated Metastatic or Unresectable Melanoma Advances Cell Therapy Franchise with FDA Approvals for Abecma and Breyanzi Presents Positive Results from POETYK-1 and POETYK-PSO-2 Phase 3 Trial Evaluating Deucravacitinib (TYK2 inhibito
- Bristol Myers Squibb Announces DividendNEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of forty-nine cents ($0.49) per share on the $.10 par value common stock of the company. The dividend is payable on May 3, 2021 to stockholders of record at the close of business on April 1, 2021. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable June 1, 2021 to stockholders of record at the close of business on May 4, 2021. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to disc
- Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2020, which reflect robust sales, strong operating performance and advancement of the company’s product pipeline. “In our first full year as a new company we delivered solid operational and financial results, and laid a strong foundation for the future,” said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb. “I am grateful to our team whose resilience and continued focus enabled us to grow our inline business, launch promising new drugs and significantly advance our pipeline while keeping our colleagues safe and maintaining th
- Bristol Myers Squibb Announces Dividend IncreaseNEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of forty-nine cents ($.49) per share on the $.10 par value common stock of the company. The dividend is payable on February 1, 2021 to stockholders of record at the close of business on January 4, 2021. This amount represents an 8.9% increase in the quarterly dividend over last year’s quarterly rate of forty-five cents ($.45) per share. At this quarterly dividend rate, subject to the normal quarterly review by the Board of Directors, the annual dividend rate for the fiscal year 2021 is $1.96 per share. This marks the twelfth consecutive fiscal yea